(Q24791107)

3

0 references

Ian A Cree

12

object named as

Ian A Cree

0 references

Louise A Knight

4

object named as

Louise A Knight

0 references

author name string

Sanjay Sharma

1

0 references

Michael H Neale

2

0 references

Pauline A Whitehouse

5

0 references

Stuart J Mercer

6

0 references

Bernard R Higgins

7

0 references

Alan Lamont

8

0 references

Richard Osborne

9

0 references

Andrew C Hindley

10

0 references

Christian M Kurbacher

https://scigraph.springernature.com/pub.10.1186/1471-2407-3-19

11

0 references

language of work or name

English

0 references

publication date

3 July 2003

0 references

published in

BMC Cancer

0 references

volume

3

0 references

issue

1

0 references

page(s)

19

0 references

exact match

0 references

cites work

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

7 April 2017

Cancer statistics, 2001

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Phase II evaluation of 3-day topotecan with cyclophosphamide in the treatment of recurrent ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Treatment of advanced ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Advanced epithelial ovarian cancer: 1998 consensus statements

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Comparison of MTT and ATP-based assays for the measurement of viable cell number

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Individualizing chemotherapy for solid tumors--is there any alternative?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

30 May 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

"Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Treatment preferences in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Methotrexate chemosensitivity by ATP luminescence in human leukemia cell lines and in breast cancer primary cultures: comparison of the TCA-100 assay with a clonogenic assay.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=166157

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

28 November 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Justification for evaluating new anticancer drugs in selected untreated patients with extensive-stage small-cell lung cancer: an Eastern Cooperative Oncology Group randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

The ex vivo chemosensitivity profile of choroidal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-3-19

Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12841853

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/12841853